Product Description
Elvitegravir is a modified quinolone antibiotic with activity against human immunodeficiency virus 1. Elvitegravir is an inhibitor of viral integrase and retains activity against integrase mutants that are resistant to Raltegravir. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Elvitegravir)
Mechanisms of Action: HIV Integrase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: HIV Infections
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2015-000313-40 |
2015-000313-40 | P3 |
Completed |
HIV Infections |
2024-05-25 |
2025-05-25 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ACTRN12619001607167p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Healthy Volunteers |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/30/2025 |
News Article |
Gilead Sciences Announces Third Quarter 2025 Financial Results |
|
08/07/2025 |
News Article |
Gilead Sciences Announces Second Quarter 2025 Financial Results |
|
04/24/2025 |
News Article |
Gilead Sciences Announces First Quarter 2025 Financial Results |
|
02/11/2025 |
News Article |
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results |